Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 26, 2009

View Archived Issues

Takeda divulges novel tachykinin NK2 receptor antagonists

Novel p110alpha inhibitors with anticancer activity developed at Roche

Solvay claims novel cannabinoid CB1 receptor agonists for use as analgesic agents

Novel inhibitors of bacterial DNA gyrase and/or topoisomerase type 4 prepared and tested

Pfizer imparts MMP-13 inhibitors for the treatment of osteoarthritis

Richter-Helm and Athera sign agreement for development of recombinant protein in ACS

PharmaSurgics receives Swedish approval to initiate phase I clinical program for PXL-01

Joslin to initiate clinical trial of antiinflammatory salsalate in type 2 diabetes

Lytix raises USD 10.4 million to fund clinical development of LTX-109 and LTX-315

Meritage initiates phase IIb clinical trial of oral viscous budesonide in pediatric patients

Fenobam safe, affects behavior in patients with Fragile X syndrome

Splice-switching oligonucleotide induces RNA repair in model of beta-thalassemia

Cladribine significantly reduced relapse rate of MS in phase III pivotal trial

CONFIRM 1 trial for voclosporin-coated coronary stent system fully enrolled

GSK's pediatric pneumococcal candidate vaccine receives positive opinion

MabThera receives positive E.U. opinion for first-line treatment of CLL

DiaKine reports results from preclinical mouse study of lisofylline in type 2 diabetes

Lexicon restructures operations to direct resources towards core therapeutic areas

FDA approves Geron's IND for phase I clinical trial of GRNOPC-1 in spinal cord injury

Cobra and Scancell sign GMP agreement for SCIB-1 DNA cancer vaccine

GSK acquires UCB's product portfolio across certain territories for EUR 515 million

European Commission withdraws marketing authorization for Roche's Zenapax

Alnylam receives FDA clearance to initiate phase I ALN-VSP study

Glenmark files phase I trial application with MHPRA for GRC-15300

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...